Britannia Life Sciences Inc.
BLAB
CNSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -278.88% | -219.76% | -223.11% | -66.48% | -78.54% |
| Total Depreciation and Amortization | -23.75% | -23.39% | -11.76% | 12.07% | 27.72% |
| Total Amortization of Deferred Charges | -- | 48.66% | -16.03% | -66.41% | -- |
| Total Other Non-Cash Items | 267.50% | 309.68% | -14.29% | -223.57% | 64.87% |
| Change in Net Operating Assets | -51.84% | -34.29% | 824.15% | 614.73% | 460.37% |
| Cash from Operations | -63.25% | -50.99% | -56.97% | -43.56% | 2.91% |
| Capital Expenditure | 86.32% | 88.01% | 92.36% | 136.74% | -120.86% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -446.97% | -446.97% | 65.22% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -616.73% | -136.27% | -8.41% | 59.13% | 87.53% |
| Cash from Investing | 80.68% | 66.31% | -167.33% | -49.36% | 59.02% |
| Total Debt Issued | -- | 3,197.01% | 3,197.01% | -- | -- |
| Total Debt Repaid | -18.56% | -86.98% | -140.62% | -187.55% | 71.96% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 55.64% | 13.58% | 4.66% | -56.90% | -185.21% |
| Foreign Exchange rate Adjustments | 195.04% | -22.68% | -27.34% | -120.62% | -84.69% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 74.24% | -0.43% | -380.45% | -305.12% | -230.16% |